RET and breast carcinoma: In an ex vivo culture model of resected human BCBM, representing multiple breast cancer histologic subtypes, it was observed that treatment with either Cabozantinib (which inhibits RET along with MET, AXL, KIT, VEGFR and FLT3), or the pan-HER kinase inhibitor Afatinib was effective in the reduction of cell viability.